Quick Facts

• May be utilized to manage serious bacterial infections in specific situations.
• Topical formulations can be used for certain eye infections, such as bacterial conjunctivitis.
• Its systemic use is generally reserved for severe conditions when other suitable options are unavailable.

---

Левомицетин, also known by its chemical name chloramphenicol, is an antimicrobial agent used to address a range of bacterial infections. Its systemic use, meaning administration by mouth or injection, is typically reserved for serious and life-threatening infections, particularly when other less potentially hazardous drugs have been determined to be ineffective or inappropriate. This restriction is based on safety considerations.

This medication has been utilized in the clinical management of serious systemic infections such as typhoid fever (caused by Salmonella typhi) and certain forms of meningitis. It may also be applied topically in formulations like eye drops or ointments to address specific superficial eye infections, including bacterial conjunctivitis.

In circumstances where it is deemed necessary, chloramphenicol is considered appropriate for use against susceptible organisms that cause serious gram-negative bacterial infections, rickettsial infections, and select conditions involving Haemophilus influenzae. Patients must consult with a healthcare professional to determine if this therapy is a suitable choice for their specific condition.

---

Левомицетин, known generically as Chloramphenicol, is a potent antibiotic typically reserved for serious infections where safer alternatives are ineffective, due to its risk of severe side effects.

Who Can Use Chloramphenicol (Левомицетин)?

Systemic formulations (oral or intravenous) are generally for life-threatening bacterial infections, such as typhoid fever or certain forms of meningitis, in adults and children when the infection is confirmed or suspected to be susceptible only to this drug. Topical forms (eye drops, ointments, and ear drops) are used for treating external bacterial infections.

Who Cannot Use Chloramphenicol (Левомицетин)?

This medication is contraindicated and should be avoided in individuals with:

• Known hypersensitivity or allergic reaction to Chloramphenicol or any components of the formulation.
• A history of bone marrow depression or any conditions leading to low blood cell counts (blood dyscrasias).
• Acute porphyria, a metabolic disorder.
• Trivial or non-severe infections where its potent risks outweigh the potential benefits.

It is generally not recommended for:

• Infants, particularly newborns and premature infants, due to the risk of developing Gray Baby Syndrome, a severe and often fatal form of toxicity.
• Pregnant individuals, especially near term, as the systemic drug can cross the placenta and potentially cause the Gray Baby Syndrome in the neonate.
• Breastfeeding mothers, as the drug passes into breast milk and poses risks, including bone marrow suppression and Gray Baby Syndrome, to the infant. Alternative feeding methods are usually advised during systemic treatment.

Chloramphenicol (Левомицетин) is associated with several clinically important interactions, primarily due to its effect as an inhibitor of hepatic microsomal enzymes, such as cytochrome P450 isoforms CYP2C19 and CYP3A4. This mechanism can reduce the metabolism of certain co-administered drugs, potentially leading to increased plasma concentrations and risk of toxicity.

Documented Interacting Medicines and Products

Classification	Specific Interacting Agents/Classes
Increased Plasma Levels	Anticonvulsants (e.g., Phenytoin, Fosphenytoin), Immunosuppressants (Tacrolimus), Anticoagulants (e.g., Dicumarol, Warfarin), Sulfonylureas (e.g., Chlorpropamide, Tolbutamide), and CYP3A4 substrates (e.g., Voriconazole, Cyclosporine)
Decreased Effect	Live Vaccines (Cholera Vaccine, Live, Typhoid Vaccine, Live), some Beta-Lactam antibiotics (Antagonism)
Altered Chloramphenicol Levels	Hepatic Enzyme Inducers (e.g., Rifampin) may decrease Chloramphenicol concentration
Other Interactions	Alcohol and Tobacco use may cause interactions that require consultation.

When co-administration with these listed products is necessary, regulatory information indicates that a change in the dose or frequency of use of one or both medicines may be required to manage the interaction risk. Combinations with live bacterial vaccines are generally contraindicated due to a risk of decreased therapeutic efficacy of the vaccine.

Molecular Blockade of Protein Synthesis: The Core Mechanism

Левомицетин (Chloramphenicol) acts by binding reversibly to the large 50S ribosomal subunit found in susceptible bacteria. This interaction creates a steric blockade within the Peptidyl Transferase Center (PTC). The blockade prevents the enzyme from catalyzing the formation of peptide bonds between incoming aminoacyl-tRNA and the growing peptide chain, thus directly inhibiting the elongation phase of bacterial protein synthesis.

---

Physiological Effect: Bacteriostatic Growth Arrest

The resulting cessation of new protein synthesis leads to the drug's primary physiological consequence: a bacteriostatic effect. By arresting the construction of essential structural and enzymatic proteins, the drug halts the growth and reproduction of the bacterial population. This action results in the functional arrest of bacterial proliferation, which functionally creates a dependency on the host's immune response for clearance of the non-multiplying organisms.

---

Mechanistic Limitations

The action is functionally constrained by bacterial resistance mechanisms, notably the enzyme Chloramphenicol Acetyltransferase (CAT), which inactivates the drug, and efflux pumps, which reduce its concentration at the target site. The drug also exhibits limited target selectivity, as it can bind to structurally similar mammalian mitochondrial ribosomes (mitoribosomes).

Chloramphenicol (Левомицетин) administration follows guidelines defined by the intended site of action, using systemic (intravenous or oral) or local (topical ophthalmic/otic) routes.

Systemic Administration and Dosing

For systemic use, the standard adult regimen is a total daily dose of 50 mg/kg of body weight. This dose must be partitioned into four equal portions and delivered at precise six-hour intervals to maintain the required concentration throughout the course. Treatment duration for systemic infections typically extends for 10 to 14 days.

The intravenous form, chloramphenicol sodium succinate, is for IV use only as the intramuscular route is ineffective. The powder requires reconstitution to a 100 mg/mL concentration with an aqueous diluent, and the resulting solution must be injected over at least a one-minute interval. Oral formulations, such as capsules, may be administered with or without food.

Population and Local Use Rules

Dosage modification is required for certain populations. Neonates under two weeks of age are restricted to a total dose of 25 mg/kg per day due to metabolic considerations. Dosage adjustments are also necessary for patients with impaired hepatic or renal function.

For topical ophthalmic use, the dosing begins with a high frequency, often every two hours during waking hours, which is reduced after the initial 48 hours. The use pattern dictates that application should continue for at least 48 hours after the eye appears normal to complete the course.

Research Evidence / Overview of Studies for Левомицетин (Chloramphenicol)

---

Evidence for Use in Severe Systemic Infections

Research on the systemic use of Chloramphenicol (Левомицетин) was studied for and was evaluated in the context of severe and life-threatening conditions such as typhoid fever (enteric fever) and certain types of bacterial meningitis. These studies examined how research explored the drug alongside other antibiotics studied at that time. Researchers monitored outcomes related to physiological strain or stress such as overall mortality (death rate), treatment failure, and time until fever resolved (defervescence).

Studies were conducted during periods of increased symptom activity in patients of all ages, including children and adults. The research landscape is based on a body of older, comparative trials. As a result, the research highlights changes measured during the study period but does not determine whether an individual will respond similarly to current standard treatments.

---

Evidence for Use in Topical Ophthalmic Infections

The topical formulation of Chloramphenicol was studied for use in superficial eye conditions, most notably bacterial conjunctivitis. The research available for this use includes numerous Randomized Controlled Trials (RCTs) and meta-analyses that compared the topical antibiotic to a placebo (inactive substance) and to other topical antibiotics. Studies monitored how patient-reported outcomes describing perceived discomfort, and research examined outcomes related to irritative states.

Research provides insight into short-term changes, with most key outcomes measured within one week of starting treatment. The research provides limited insight into outcomes reflecting daily functioning versus the natural progression of the condition. The evidence is limited by the finding that many cases of conjunctivitis are viral, which may not be susceptible to the antibiotic being studied.

---

Long-Term Studies and Follow-up Durations

For systemic use, follow-up durations were limited, typically extending only during the acute treatment period. This means that long-term effects are not fully established regarding the durability of the response or whether the drug was associated with patterns of relapse/exacerbation frequency over many months or years. For topical use, follow-up durations were limited, typically assessing the primary outcome by Day 7. Overall, long-term effects are not fully established for either major indication.

---

Areas of Uncertainty and Evidence Gaps

For systemic use, a key gap is the heavy reliance on older evidence. The comparative evidence is lacking for Chloramphenicol versus current antibiotic protocols in many severe infection contexts. For topical use, the main uncertainty involves the limited information about the drug was evaluated in trials versus the natural course of the self-resolving condition. Evidence is limited in providing clear findings for all specific high-risk patient groups.

Key Studies & References Management of Typhoid Fever and Bacterial Meningitis by Chloramphenicol in Infants and Children

Common questions about Левомицетин (FAQ)

Q: Does this medication make you sleepy?

Regulatory information for this type of medication lists possible Central Nervous System (CNS) effects such as dizziness or somnolence (drowsiness) as potential side effects. If these effects occur, official guidance states that caution should be exercised when driving or operating heavy machinery.

Q: What should I do if I miss a dose?

The official directions for using the medication typically address this scenario. Generally, instructions state that users should take the next dose at the regularly scheduled time and not double the dose in an attempt to compensate for the one they missed. This is based on specific instructions provided in the regulatory product leaflet.

Q: Can I take this to treat migraines?

According to the official product information, this drug is indicated for the temporary relief of minor aches and pains. While it may address certain types of pain, specific medical conditions such as a migraine may or may not be explicitly included in the labeled therapeutic indications. Patients should use the medication only for the conditions listed on the official label.

Q: What conditions would prevent me from taking this?

Regulatory documents list specific contraindications, which are conditions where the drug should generally not be used. Common examples include a history of severe allergic reactions to this drug or related NSAIDs, pregnancy (especially in the third trimester), and certain existing conditions like recent gastrointestinal bleeding or ulcers.

Q: Does this drug interact with alcohol?

Official warnings note that consuming alcohol while taking this medication can increase risk. Specifically, if a person consumes three or more alcoholic drinks daily, there may be an increased risk of serious side effects, such as stomach bleeding. The official label provides comprehensive details regarding alcohol use.

Q: Can children 2 years old use it?

Official drug labels contain specific usage instructions for children, including a minimum age limit and detailed dosing. Depending on the formulation, the product may or may not be labeled for use in children as young as 2 years old. Official product information should be consulted for specific age and weight restrictions.

Official Storage and Disposal Instructions for Левомицетин (Chloramphenicol)

Storage of Левомицетин must strictly adhere to regulatory guidelines to maintain potency and stability.

---

Storage Requirements

Category	Requirement
Temperature	Store most preparations at controlled room temperature (15 C to 30 C); do not freeze.
Protection	Keep the medicine protected from light and store in its original container, which must be tightly closed.
Stability Limits	Reconstituted injection solutions and opened eye drops must be discarded after a specified period (e.g., 28 to 30 days), even if the container is not empty.
Child Safety	Store the product out of the reach and sight of children.

---

Disposal Instructions

Unused or expired medicine must not be disposed of via wastewater or household trash. The product must be discarded in a manner that complies with local requirements for the disposal of pharmaceutical waste.